Royal Medical Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Royal Medical Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $96.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Royal Medical Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $96.0K Trade | TransData Nexus

Royal Medical Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $96.0K Total Trade · DGFT Verified

Royal Medical Private Limited is an Indian pharmaceutical exporter with a total trade value of $96.0K across 6 products in 2 therapeutic categories. Based on 71 verified export shipments from Indian Customs (DGFT) records, Royal Medical Private Limited is the #1 Indian exporter in 1 product including Cabozantinib. Top exports include Ledipasvir ($29.0K), Pazopanib ($28.7K), Ibrutinib ($17.6K).

Royal Medical Private Limited — Export Portfolio & Destination Treemap

Royal Medical Private Limited pharmaceutical export portfolio — 6 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Royal Medical Private Limited? — Company Overview & Market Position

Royal Medical Private Limited, incorporated on May 27, 2005, is a private unlisted company based in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U52310MH2005PTC153573. Its authorized capital is ₹50.0 lakhs, with a paid-up capital of ₹25.0 lakhs. The registered office is located at Office No. 2, 1st Floor, Sunbeam Chambers, 7, New Marine Lines, Opp. Liberty Cinema Building, Mumbai, Maharashtra 400020.

Royal Medical Private Limited specializes in the wholesale trading of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company has been operational for over two decades, indicating a stable presence in the pharmaceutical export sector. As of the latest available data, the company has a paid-up capital of ₹25.0 lakhs, reflecting its financial standing.

What Does Royal Medical Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ledipasvir$29.0K 2

Product Portfolio — Top 6 by Export Value

Royal Medical Private Limited exports 6 pharmaceutical products across 2 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ledipasvir	Antiviral & HIV Medications	$29.0K	9	2.6%	3
2	Pazopanib	Advanced Oncology	$28.7K	16	0.3%	8
3	Ibrutinib	Advanced Oncology	$17.6K	14	1.7%	10
4	Cabozantinib	Advanced Oncology	$12.0K	13	9.4%	1
5	Axitinib	Advanced Oncology	$5.6K	9	6.0%	6
6	Chlorambucil	Advanced Oncology	$3.2K	10	0.9%	10

Royal Medical Private Limited exports 6 pharmaceutical products across 2 therapeutic categories with a total export value of $96.0K. The company is the #1 Indian exporter in 1 product: Cabozantinib. The top category is Advanced Oncology (69.8% of portfolio), followed by Antiviral & HIV Medications (30.2%), indicating a concentrated portfolio with the top 5 products accounting for 96.7% of total export value.

Royal Medical Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Royal Medical Private Limited's manufacturing facilities are not publicly disclosed. The company is primarily engaged in the wholesale trading of pharmaceutical products, suggesting that it may source its products from third-party manufacturers. Without explicit information on in-house manufacturing capabilities, it is prudent to assume that the company relies on external manufacturing partners for its product offerings.

3Key Leadership

The leadership team of Royal Medical Private Limited comprises:

Asan Mohideen Nagoormeeran Sheik Packeer: Whole-Time Director
Saumil Mahendra Gandhi: Director
Mahendra Mukundlal Gandhi: Managing Director

These individuals are responsible for steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Royal Medical Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Royal Medical Private Limited's export activities are primarily focused on the pharmaceutical sector, with a total export value of $96,000 USD across 71 shipments. The company's product portfolio includes six products across two therapeutic categories: Advanced Oncology (69.8%) and Antiviral & HIV Medications (30.2%). Notably, the company holds the #1 market position in Cabozantinib, with a 9.4% market share. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The absence of this information suggests that the company may not have significant market penetration in these regions or that such data is not disclosed.

2Emerging Markets

Royal Medical Private Limited's export data indicates a focus on markets in Africa, South Africa, and potentially other regions. The company's engagement in these markets is facilitated by its membership in the Pharmaceuticals Export Promotion Council, which supports Indian pharmaceutical exporters in accessing global markets. While the company has a presence in emerging markets, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly disclosed.

3Geographic Strategy

Royal Medical Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Royal Medical Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The absence of this information suggests that the company may not have significant operations or approvals in the United States market. Without explicit data, it is challenging to assess the company's standing with the FDA.

2WHO & EU GMP

There is no publicly available information indicating that Royal Medical Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The lack of such certifications may limit the company's ability to access certain international markets that require these standards. However, the company's membership in the Pharmaceuticals Export Promotion Council suggests a commitment to international trade and adherence to certain quality standards.

3CDSCO & Indian Regulatory

Royal Medical Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Royal Medical Private Limited operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. The company's top five products—Cabozantinib, Axitinib, Ledipasvir, Pazopanib, and Ibrutinib—are all oncology medications, indicating a specialized product portfolio. While specific market share data for competitors in these therapeutic categories is not available, the company's concentration in a niche segment may position it against specialized competitors in the oncology pharmaceutical market. The lack of detailed competitive analysis suggests that the company may benefit from conducting a comprehensive market study to identify key competitors and assess its competitive positioning.

2Key Differentiators

Royal Medical Private Limited's key differentiators include its specialized focus on oncology medications, particularly Cabozantinib, where it holds the #1 market position with a 9.4% market share. This specialization may allow the company to leverage expertise and establish strong relationships within the oncology pharmaceutical sector. However, the company's heavy reliance on a limited product portfolio (top five products accounting for 96.7% of total exports) may pose risks related to market concentration.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Royal Medical Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Royal Medical Private Limited's export data indicates a consistent volume of shipments, with 71 shipments totaling $96,000 USD. The company's focus on finished pharmaceutical formulations suggests a commitment to quality and compliance with international standards. However, the lack of detailed information regarding manufacturing facilities, regulatory approvals, and certifications makes it challenging to fully assess the reliability and consistency of the company's supply chain. Potential partners should conduct thorough due diligence to ensure alignment with their quality and regulatory requirements.

2Certifications to Verify

Importers should verify the following certifications when considering Royal Medical Private Limited as a supplier:

WHO-GMP Certification: Ensures compliance with World Health Organization Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting the company directly.

EU GMP Certification: Confirms adherence to European Union Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the company.

Frequently Asked Questions — Royal Medical Private Limited

How many pharmaceutical products does Royal Medical Private Limited export from India?

Royal Medical Private Limited exports 6 pharmaceutical products across 2 therapeutic categories. The top exports are Ledipasvir ($29.0K), Pazopanib ($28.7K), Ibrutinib ($17.6K), Cabozantinib ($12.0K), Axitinib ($5.6K). Total export value is $96.0K.

What is Royal Medical Private Limited's total pharmaceutical export value?

Royal Medical Private Limited's total pharmaceutical export value is $96.0K, based on 71 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Royal Medical Private Limited the #1 Indian exporter?

Royal Medical Private Limited is the #1 Indian exporter in 1 products: Cabozantinib (9.4% market share).

What therapeutic categories does Royal Medical Private Limited cover?

Royal Medical Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (69.8%, 5 products), Antiviral & HIV Medications (30.2%, 1 products).

Get Full Royal Medical Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.